Rebecca Cohen


Rebecca Cohen is a corporate strategy and investor relations leader in the biotech industry. She has been a part of the Ikena corporate strategy team since 2021, leading the investor relations program and communications strategy. She previously led these functions at SQZ Biotech (formerly NYSE: SQZ) where she was instrumental in the company’s IPO and several private raises. Prior to SQZ, Rebecca consulted in IR at Burns McClellan for a variety of clients, including Kite Pharma (formerly NASDAQ:KITE) and Intra-Cellular Therapies (NASDAQ:ITCI) . Over the course of her career, she has been a part of raising over $500 million in capital, as well as the acquisition and integration of multiple assets and companies. She began her career in clinical and medical affairs at Mesoblast (NASDAQ:MESO, ASX:MSB), an Australian cell therapy company. Rebecca has an undergraduate degree in chemistry from Rutgers University. Rebecca serves on the board of Schechter Boston and Jewish Big Brother Big Sister, where she is also a big sister in the Friend to Friend program.

Scroll to Top